Business Description
Viking Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92686J1060
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 815.39 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.2 | |||||
3-Year EPS without NRI Growth Rate | -18.9 | |||||
3-Year FCF Growth Rate | -37.4 | |||||
3-Year Book Growth Rate | 1.4 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.5 | |||||
9-Day RSI | 56.82 | |||||
14-Day RSI | 56.28 | |||||
6-1 Month Momentum % | 473.41 | |||||
12-1 Month Momentum % | 200.82 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 29.48 | |||||
Quick Ratio | 29.48 | |||||
Cash Ratio | 29.38 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | -7.47 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -21.59 | |||||
ROA % | -20.64 | |||||
ROIC % | -7011.83 | |||||
ROC (Joel Greenblatt) % | -9535.02 | |||||
ROCE % | -26.28 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 8.56 | |||||
Price-to-Tangible-Book | 9.11 | |||||
EV-to-EBIT | -66.8 | |||||
EV-to-Forward-EBIT | -53.09 | |||||
EV-to-EBITDA | -66.98 | |||||
EV-to-Forward-EBITDA | -53.09 | |||||
EV-to-FCF | -128.18 | |||||
Price-to-Projected-FCF | 20.97 | |||||
Price-to-Net-Current-Asset-Value | 9.12 | |||||
Price-to-Net-Cash | 9.15 | |||||
Earnings Yield (Greenblatt) % | -1.5 | |||||
FCF Yield % | -0.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Viking Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.93 | ||
Beta | 7.09 | ||
Volatility % | 235.84 | ||
14-Day RSI | 56.28 | ||
14-Day ATR ($) | 4.032921 | ||
20-Day SMA ($) | 72.885665 | ||
12-1 Month Momentum % | 200.82 | ||
52-Week Range ($) | 8.8834 - 99.295 | ||
Shares Outstanding (Mil) | 110.27 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Viking Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Viking Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Viking Therapeutics Inc Frequently Asked Questions
What is Viking Therapeutics Inc(LTS:0VQA)'s stock price today?
When is next earnings date of Viking Therapeutics Inc(LTS:0VQA)?
Does Viking Therapeutics Inc(LTS:0VQA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |